Ipsen executive urges scientists to look beyond first results to achieve patient impact

Philippe Lopes-Fernandes, executive vice president and chief business officer at Ipsen, reflects on how scientific progress often requires moving past an initial finding. He notes that a result can confirm a hypothesis, challenge it, or point to a new question, and that the first answer is only a starting point.

The article stresses that speed is vital when patients face complex, life‑limiting diseases, but judgment is equally important. Lopes‑Fernandes argues that the right decision may be to accelerate, to pause, or to examine data more closely to uncover hidden potential. He cites past breakthroughs that emerged from asking different questions rather than following a single data point.

Ipsen’s strategy, according to the piece, blends disciplined evidence‑following with the courage to pursue overlooked opportunities. This mindset shapes its portfolio across oncology, rare disease and neuroscience, where the company builds deep expertise and partnerships to translate scientific insights into patient‑focused impact.